Allianz SE Raises Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Key Points

• Allianz SE increased its stake in Eli Lilly and Company by 3.5%, acquiring an additional 1,324 shares, bringing their total holdings to $32.38 million.
• Eli Lilly reported earnings of $3.34 per share for the quarter, missing analysts' estimates of $4.64, while revenue increased 45.2% year-over-year.
• The company announced a quarterly dividend of $1.50 per share, with a 0.8% annualized yield, expected to be paid on September 10th.

Allianz SE lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.5% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 39,201 shares of the company's stock after acquiring an additional 1,324 shares during the period. Eli Lilly and Company accounts for approximately 0.9% of Allianz SE's portfolio, making the stock its 21st biggest position. Allianz SE's holdings in Eli Lilly and Company were worth $32,376,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. WestEnd Advisors LLC increased its position in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the last quarter. Citizens National Bank Trust Department increased its position in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $40,000. Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $43,000. Finally, O Brien Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after purchasing an additional 12 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

NYSE LLY traded up $5.42 on Monday, reaching $767.75. The stock had a trading volume of 3,348,700 shares, compared to its average volume of 3,528,007. The stock has a market cap of $727.63 billion, a P/E ratio of 62.47, a price-to-earnings-growth ratio of 1.08 and a beta of 0.44. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The business's 50-day moving average price is $775.51 and its 200 day moving average price is $800.52. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. During the same period last year, the company posted $2.58 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio is 48.82%.

Analyst Ratings Changes

A number of analysts recently issued reports on LLY shares. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their target price for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price for the company. UBS Group dropped their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.